0
0
11/11/22 at 4:35am
Organization
PMLiVE
28 words
0
Comments
Olaparib has been shown to cut the risk of cancer recurrence and improve survival
You are the first to view
https://www.pmlive.com/pharma_news/icr_calls_for_further_discussions_following_nices_rejection_of_breast_cancer_drug_1480672
Create an account
or login to join the discussion